To decipher the molecular mechanisms by which PI3K/SHP2 dual inhibition decreases cancer cell viability, we assessed the short- and long-term effects of SHP2i and/or PI3Ki on the ERK/MAPK and PI3K pathways in vivo. The gene discussed is PTPN11; the disease is cancer.